Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | EDNRB | P24530 | 1/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD5 | P21918 | 1/20 | 0.30 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5952420 | 0.88 | ABL1 (0.33) | ABL1ABCB1BCRPTPN1HDAC4 | |
| SCHEMBL2510724 | 0.87 | — | — | |
| SCHEMBL2513730 | 0.87 | — | — | |
| SCHEMBL5951380 | 0.85 | ABL1 (0.35) | ABL1ABCB1BCRPTPN1HDAC4 | |
| SCHEMBL5953290 | 0.84 | ABL1 (0.32) | ABL1ABCB1BCRPTPN1 | |
| SCHEMBL5951814 | 0.84 | BACE1 (0.33) | ABL1ABCB1BCRPTPN1HDAC4 | |
| SCHEMBL5952444 | 0.84 | ABL1 (0.33) | ABL1ABCB1BCRPTPN1HDAC4 | |
| SCHEMBL2512461 | 0.84 | GSTP1 (0.33) | HDAC4HDAC2HDAC8 | |
| SCHEMBL2516263 | 0.84 | EDNRB (0.31) | EDNRBEDNRA | |
| SCHEMBL273012 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034886-B2 | Process for manufacturing high to ultra high molecular weight polymers using novel bridged metallocene catalysts | TICONA GMBH (DE) | 2011-10-11 | — | — | US | disclosed |
| US-20100056737-A1 | Process for manufacturing high to ultra high molecular weight polymers using novel bridged metallocene catalysts | NUTRINOVA NUTRITION SPECIALTIES & FOOD INGREDIENTS GMBH (DE) | 2010-03-04 | — | — | US | disclosed |
| US-7598329-B2 | Process for manufacturing ultra high molecular weight polymers using novel bridged metallocene catalysts | TICONA GMBH (DE) | 2009-10-06 | — | — | US | disclosed |
| US-20070105712-A1 | Process for manufacturing ultra high molecular weight polymers using novel bridged metallocene catalysts | NUTRINOVA NUTRITION SPECIALTIES & FOOD INGREDIENTS GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-7038070-B2 | Preparation of preparing substituted indanones | BASELL POLYOLEFINE GMBH (DE) | 2006-05-02 | — | — | US | disclosed |
| US-6984743-B1 | Method for producing metallocenes | BASELL POLYOLEFINE GMBH (DE) | 2006-01-10 | — | — | US | disclosed |
| US-6963017-B2 | Preparation of preparing substituted indanones | BASELL POLYOLEFINE GMBH (DE) | 2005-11-08 | — | — | US | disclosed |
| EP-0968158-B1 | METHOD OF PREPARING SUBSTITUTED INDANONES, THE SUBSTITUTED INDANONES AND METALLOCENES PREPARED THEREFROM | BASELL POLYOLEFINE GMBH (DE) | 2005-08-10 | — | — | EP | disclosed |
| US-20050033076-A1 | Preparation of preparing substituted indanones | EQUISTAR CHEMICALS, LP | 2005-02-10 | — | — | US | disclosed |
| US-20030009046-A1 | Preparation of preparing substituted indanones | EQUISTAR CHEMICALS, LP | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050033076-A1 | Preparation of preparing substituted indanones | CYP1A2, CYP2J2, IDH3A | ABL1 781/4885ABCB1 1146/4885BCR 3263/4885 |
| US-20030009046-A1 | Preparation of preparing substituted indanones | CYP1A2, CYP1B1, CYP1A1 | ABL1 839/4885ABCB1 1132/4885BCR 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.